↓ Skip to main content

Recent Advances in Prolactin Research

Overview of attention for book
Attention for Chapter 10: Prolactin-induced prostate tumorigenesis.
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Prolactin-induced prostate tumorigenesis.
Chapter number 10
Book title
Recent Advances in Prolactin Research
Published in
Advances in experimental medicine and biology, January 2015
DOI 10.1007/978-3-319-12114-7_10
Pubmed ID
Book ISBNs
978-3-31-912113-0, 978-3-31-912114-7
Authors

Lucila Sackmann-Sala, Vincent Goffin

Abstract

The physiological role of prolactin (PRL) in the prostate gland is not clearly understood. Genetically-modified mouse models that have invalidated actors of the PRL signaling axis failed to identify an essential regulatory function on this tissue. However, a large body of evidence suggests an important role for PRL in prostate tumorigenesis. Mainly through the activation of its downstream target STAT5, PRL can induce growth and survival of prostate cancer cells and tissues in several experimental settings. In the clinic, PRL expression and STAT5 activation in human prostate tumors correlate with disease severity. Available data point to a role of local (autocrine/paracrine) rather than circulating (endocrine) PRL in the induction of disease progression. In mice, transgenic expression of PRL in the prostate leads to enhanced epithelial hyperplasia and dysplasia, with amplification of basal/stem cells which have been recently identified as prostate cancer-initiating cells. Thus, targeting PRL receptor (PRLR)/STAT5 signaling may provide an alternative therapy for the treatment of prostate cancer. Corresponding targeted therapies currently in preclinical development include antagonists or blocking antibodies for the PRLR and small molecule inhibitors directed against the tyrosine kinase JAK2 upstream of STAT5. Present efforts are aimed at validating these therapies for the treatment of prostate cancer, while understanding the mechanisms of disease progression induced by PRL/STAT5.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 25 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 4 16%
Student > Master 4 16%
Researcher 3 12%
Student > Ph. D. Student 3 12%
Student > Postgraduate 2 8%
Other 5 20%
Unknown 4 16%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 9 36%
Medicine and Dentistry 6 24%
Agricultural and Biological Sciences 4 16%
Computer Science 1 4%
Arts and Humanities 1 4%
Other 0 0%
Unknown 4 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2014.
All research outputs
#9,363,041
of 11,714,806 outputs
Outputs from Advances in experimental medicine and biology
#1,781
of 3,114 outputs
Outputs of similar age
#173,036
of 256,082 outputs
Outputs of similar age from Advances in experimental medicine and biology
#137
of 293 outputs
Altmetric has tracked 11,714,806 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,114 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 256,082 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 293 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.